ARS Pharma suffered a sharp selloff after CVS Health announced it is pushing its formulary review decision on Neffy — ARS's FDA-approved intranasal epinephrine alternative to the EpiPen — into January. The deferral strips away what had been a significant near-term catalyst for ARS, as CVS formulary inclusion would have opened access to millions of covered lives and validated the product commercially.

For ARS Pharma, CVS coverage was more than a revenue event — it represented a key signal for payer acceptance broadly. Competitors and legacy EpiPen makers (Pfizer/Mylan) retain formulary positioning in the interim, and every month of delay extends the window where Neffy lacks major PBM backing. CVS itself, reporting $402B in revenue with razor-thin 0.4% net margins, has limited direct financial exposure to the formulary choice but wields enormous gatekeeping power over the drug's commercial trajectory.

The January CVS decision now becomes the next binary event for ARS. A positive coverage ruling could erase today's losses and catalyze a sharp recovery; rejection or a further punt would likely accelerate the selloff and raise questions about Neffy's reimbursement path across other PBMs. Investors will also watch whether other major PBMs (Express Scripts, OptumRx) take cues from CVS's hesitation.

The setup is a classic binary overhang: the stock has already de-risked to the downside on bad news, but the January date creates a defined catalyst window. The key unknowns are what drove the delay — clinical, pricing, or administrative — and whether that signal has broader payer implications.